Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -0.40% | -.--% |
03:03pm | GSK Says Cancer Drug Jemperli Shows 100% Clinical Response Rate in Long-Term Data From Mid-Stage Trial | MT |
03:02pm | GSK immunotherapy bowel cancer drug works for 100% of patients | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 91.66B | - | ||
+40.73% | 739B | C+ | ||
+31.74% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.51% | 240B | B+ | ||
+9.60% | 210B | B- | ||
-5.28% | 206B | A+ | ||
+6.17% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GSK Stock
- GSK Stock
- Ratings GlaxoSmithKline plc